Compare KOS & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOS | AGIO |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2011 | 2013 |
| Metric | KOS | AGIO |
|---|---|---|
| Price | $2.68 | $28.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $1.76 | ★ $37.63 |
| AVG Volume (30 Days) | ★ 31.3M | 642.1K |
| Earning Date | 03-02-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,288,352,000.00 | $43,011,000.00 |
| Revenue This Year | $21.14 | $75.68 |
| Revenue Next Year | N/A | $167.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $22.24 |
| 52 Week High | $3.01 | $46.00 |
| Indicator | KOS | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 48.34 |
| Support Level | $1.53 | $26.48 |
| Resistance Level | $2.77 | $29.49 |
| Average True Range (ATR) | 0.23 | 0.92 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 69.27 | 48.37 |
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.